Compare Grab Holdings Ltd. (GRAB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Neurocrine Biosciences Inc — how do they compare? Grab Holdings Ltd. trades at $3.13 (market cap $12.60B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GRAB | NBIX | |
|---|---|---|
Market Cap | $12.60B | $14.60B |
Volume | 87,608,440 | 1,075,694 |
Sector | Technology | Health |
52-Week High | $6.17 | $185.50 |
52-Week Low | $2.80 | $123.10 |
Typical Hold Time | 94 Days | 23 Days |
Enterprise Value | $8.33B | $14.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.11, up 1.3% today, with a bearish technical signal but strong fundamentals including a 22% YoY revenue growth in Q2 2026 and a net income margin of 16.03%. Recent news highlights a $30 million CEO share purchase and the acquisition of a 60% stake in Atome Financial for $1.49 billion, signaling confidence and expansion in financial services.
The outlook is positive with robust earnings beats and a 91.67% analyst buy rating, though risks include high capital expenditure, regional regulatory challenges, and volatile cash flows. The stock's current valuation at a P/E of 28 reflects growth expectations amid competitive pressures.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
